Table 1.
Summary of Hematological Toxicity Scales Developed by the World Health Organization (WHO), National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE), Eastern Cooperative Oncology group (ECOG), and Southwest Oncology Group (SWOG).
| Grade | |||||
|---|---|---|---|---|---|
| Metric | 0 | 1 | 2 | 3 | 4 |
| WHO | |||||
| Leukocytes (x103 cells/µL) | >4.0 | 3.9–3.0 | 2.9–2.0 | 1.9–1.0 | <1.0 |
| Granulocytes (x103 cells/µL) | >2.0 | 1.9–1.5 | 1.4–1.0 | .9–0.5 | <0.5 |
| Thrombocytes (x103 cells/µL) | >100 | 99–75 | 74–50 | 49–25 | <25 |
| Hemoglobin (g/dL) | >11.0 | 10.9–9.5 | 9.4–8.0 | 7.9–6.5 | <6.5 |
| CTCAE | |||||
| Leukocytes (x103 cells/µL) | WNL | <LLN–3.0 | <3.0–2.0 | <2.0–1.0 | <1.0 |
| Granulocytes (x103 cells/µL) | WNL | <LLN–1.5 | <1.5–1.0 | <1.0–0.5 | <0.5 |
| Lymphocytes (x103 cells/µL) | WNL | <LLN–0.8 | <.8–0.5 | <.5–0.2 | <0.2 |
| Thrombocytes (x103 cells/µL) | WNL | <LLN–75 | <75–50 | <50–25 | <25 |
| Hemoglobin (g/dL) | WNL | <LLN-10.0 | <10.0-8.0 | <8.0 | |
| ECOG | |||||
| Leukocytes (x103 cells/µL) | ≥4.5 | <4.5–3.0 | <3.0–2.0 | <2.0–1.0 | <1.0 |
| Granulocytes (x103 cells/µL) | ≥1.9 | <1.9–1.5 | <1.5–1.0 | <1.0–0.5 | <0.5 |
| Thrombocytes (x103 cells/µL) | ≥130 | <130–90 | <90–50 | <50–25 | <25 |
| Hemoglobin (g/dL) | ≥11 | 10.9–9.5 | <9.5 | ||
| Hematocrit (%) | ≥32 | 31.9–28 | <28 | ||
| SWOG | |||||
| Leukocytes (x103 cells/µL) | ≥4.0 | 3.9–3.0 | 2.9–2.0 | 1.9–1.0 | <1.0 |
| Granulocytes (x103 cells/µL) | ≥2.0 | 1.9–1.5 | 1.4–1.0 | .9–0.5 | <0.5 |
| Lymphocytes (x103 cells/µL) | ≥2.0 | 1.9–1.5 | 1.4–1.0 | .9–0.5 | <0.5 |
| Thrombocytes (x103 cells/µL) | WNL | Normal–75.0 | 74.9–50.0 | 49.9–25.0 | <25.0 |
| Hemoglobin (g/dL) | WNL | Normal–10.0 | 9.9–8.0 | 7.9–6.5 | <6.5 |